Revenue segments as reported by the company.

Transcatheter Aortic Valve Replacement

Transcatheter Mitral and Tricuspid Therapies

Surgical Structural Heart

Critical Care

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general, and administrative expenses

Research and development expenses

Intellectual property litigation expenses, net

Change in fair value of contingent consideration liabilities

Special charges

Restructuring expenses

Other operating expenses, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Edwards Lifesciences

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart, and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring systems measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Edwards Lifesciences projects robust sales growth amidst market advancements

Edwards Lifesciences showcased strong sales growth and financial performance in Q4 2022. Despite challenges like FX impacts and spotty backlog, the company remains confident in its growth outlook. Encouraging opportunities lie in TMTT and Surgical Structural Heart segments for future expansion.

Edwards Lifesciences reports robust Q1 sales, eyes global expansion

Edwards Lifesciences delivered strong sales performance in Q1, driven by key product segments and global growth.
The company faces challenges in managing expenses and navigating competitive dynamics, particularly in Japan.
Opportunities lie in continued market growth, product innovation, and efficiency enhancements across operations.
Overall, Edwards Lifesciences remains well-positioned for growth and market leadership in the cardiovascular space.

Edwards Lifesciences exceeds Q2 expectations, raises full-year guidance

Edwards Lifesciences delivered strong Q2 results, raising full year guidance and highlighting growth in key segments. While facing challenges like seasonal impacts and market recovery issues, the company remains focused on innovation and market expansion.

Edwards Lifesciences excels in Q3, poised for diversified growth

Edwards Lifesciences delivered a strong Q3 performance with growth across key segments and a positive outlook for 2023.
The company's focus on innovation, differentiated sales strategies, and patient-centric initiatives position it well for future growth.
Challenges in pricing dynamics and market competition require strategic management, while opportunities in diverse therapies and patient activation initiatives offer avenues for expansion.
Overall, Edwards Lifesciences maintains a solid financial position, supported by a robust balance sheet and a commitment to long-term growth.

Edwards Lifesciences posts strong Q4 results, eyes global growth opportunities

Edwards Lifesciences' Q4 2023 performance reflects solid financial health and strategic investments for future growth. Despite facing challenges such as rising expenses and competitive pressures, the company is well-positioned to capitalize on opportunities through innovation and market expansion.

Edwards Lifesciences reports robust Q1 sales growth and outlook

Edwards Lifesciences shows strong sales growth across key segments and raises 2024 outlook.
Investments in transcatheter platforms and positive milestones drive sustainable growth.
Challenges include managing increased expenses and ensuring center readiness for new therapies.
Opportunities in AI implementation, patient care initiatives, and diversified growth potential.

Edwards Lifesciences reports strong Q3 performance and strategic growth focus

Edwards Lifesciences delivered robust Q3 results driven by TAVR and TMTT growth, showcasing resilience and innovation.
While facing challenges in certain markets like Japan, Edwards maintains a strong competitive position and strategic focus on long-term growth.
The company's acquisitions, product advancements, and maintained guidance reflect a commitment to expansion and market leadership.
With opportunities in innovation and global expansion, Edwards is poised for continued growth and success in the medical technology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Edwards Lifesciences (EW) reports strong contributions from the TMTT product group in the second quarter of 2024.

Edwards Lifesciences (EW) Q2 Earnings Meet Mark, Margins Crash

Edwards Lifesciences (NYSE: EW ) stock is down on Thursday after the heart disease care company announced earnings for its second quarter of 2024. That earnings report starts with its adjusted EPS of 70 cents.

Why Is Edwards Lifesciences (EW) Stock Down 22% Today?

Peijia to maintain exclusive rights in Greater China to commercialize JenaValve's Trilogy Transcatheter Heart Valve (THV) System SUZHOU, China , July 25, 2024 /PRNewswire/ -- Peijia Medical Limited (Peijia, (9996.HK)), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, today commented on the expected acquisition of JenaValve Technology, Inc. ("JenaValve"), an exclusive technology licensing partner of Peijia, by Edwards Lifesciences ("Edwards"). On July 24, 2024, Edwards announced that it had entered into an agreement to acquire JenaValve, a pioneer in the transcatheter treatment of aortic regurgitation (AR), a deadly disease that impacts a significant and growing population and is currently untreated today.

Peijia Medical's Licensing Partner, JenaValve Technology, Inc., is Expected to be Acquired by Edwards Lifesciences

The medical-technologies company misses second-quarter sales estimates.

Edwards Lifesciences Stock Plunges 24% After Earnings. What Wall Street Thinks.

Edwards Lifesciences Corporation (NYSE:EW ) Q2 2024 Earnings Conference Call July 24, 2024 5:00 PM ET Company Participants Mark Wilterding - SVP & IR Bernard Zovighian - CEO Scott Ullem - CFO Larry Wood - Group President of TAVR and Surgical Structural Heart Daveen Chopra - Global Leader of TMTT Conference Call Participants Larry Biegelsen - Wells Fargo Robbie Marcus - JPMorgan David Roman - Goldman Sachs Joshua Jennings - TD Cowen Travis Steed - Bank of America Matthew Taylor - Jefferies Vijay Kumar - Evercore ISI Patrick Wood - Morgan Stanley Operator Greetings, and welcome to the Edwards Lifesciences Second Quarter 2024 Results. At this time, all participants are in a listen-only mode.

Edwards Lifesciences Corporation (EW) Q2 2024 Earnings Call Transcript

While the top- and bottom-line numbers for Edwards Lifesciences (EW) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Edwards Lifesciences (EW) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Edwards Lifesciences (EW) came out with quarterly earnings of $0.70 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.66 per share a year ago.

Edwards Lifesciences (EW) Q2 Earnings Match Estimates

Edwards Lifesciences missed second-quarter revenue estimates on Thursday, hurt by lower-than-expected demand for its artificial heart valves.

Edwards Lifesciences misses Q2 revenue estimates on weak demand for heart devices

Edwards Lifesciences stock plummeted Wednesday after the medtech cut its outlook for TAVR sales following a mixed second-quarter report.

Edwards Plummets After Slashing Guidance For Its Biggest Moneymaker

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2024. Highlights and Outlook Q2 sales grew 7%; constant currency1 sales grew 8% Q2 TAVR sales grew 5%; constant currency1 sales grew 6% Q2 TMTT sales grew 75%; increasing contribution to Edwards' growth Q2 EPS of $0.61; adjusted1 EPS of $0.70 Significant TAVR and TMTT clinical evidence to be presented at TCT in October 2024 Positive EVOQUE introduction with excellent.

Edwards Lifesciences Reports Second Quarter Results

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced investments that reflect the company's deep commitment to advancing patient care through structural heart innovation, addressing large unmet patient needs and supporting sustainable long-term growth. Edwards has entered into an agreement to acquire JenaValve Technology, a pioneer in the transcatheter treatment of aortic regurgitation (AR), a deadly disease that impacts a significant and growing population and is la.

Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix

Align Technology

Boston Scientific

Thermo Fisher Scientific

Here is a sneak peek into how four MedTech bigshots, BSX, TMO, ALGN and EW, are expected to fare in their second-quarter results, slated to be released tomorrow.

Can These 4 MedTech Stocks Hit Targets This Earnings Season?

Edwards Lifesciences (EW) exercises the option to acquire Innovalve Bio-Medical Ltd., strengthening its TMVR technology portfolio and addressing unmet needs in structural heart disease.

Edwards Lifesciences (EW) Buys Innovalve to Boost TMVR Solutions

Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Edwards Lifesciences (EW) Reports Next Week: Wall Street Expects Earnings Growth

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2024 after the market closes on Wednesday, July 24, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com. About Edwards Li.

Edwards Lifesciences to Host Earnings Conference Call on July 24, 2024

Edwards Lifesciences' (EW) TMTT segment's PASCAL platform is likely to have maintained strong growth momentum in the second quarter globally, backed by its portfolio of differentiated therapies.

Is a Beat Likely for Edwards Lifesciences (EW) in Q2 Earnings?

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced it has exercised its option to acquire Innovalve Bio Medical Ltd., an early-stage transcatheter mitral valve replacement (TMVR) company, following its initial investment in 2017. Since that time, Innovalve has demonstrated progress in its program with promising early clinical experience. Combined with Edwards' existing mitral innovations, the acquisition enhances the company's TMVR technologies to address large unm.

Edwards Lifesciences to Acquire Innovalve

Hologic

Investors looking for stocks in the Medical - Instruments sector might want to consider either Hologic (HOLX) or Edwards Lifesciences (EW). But which of these two stocks offers value investors a better bang for their buck right now?

HOLX or EW: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Instruments sector have probably already heard of Hologic (HOLX) and Edwards Lifesciences (EW). But which of these two stocks offers value investors a better bang for their buck right now?

HOLX vs. EW: Which Stock Is the Better Value Option?

HOLX vs. EW: Which Stock Should Value Investors Buy Now?

NEW YORK--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced the results from an analysis of data from the PARTNER Trials examining outcomes of transcatheter aortic valve replacement (TAVR) patients with a small annulus. Through five-year follow up of more than 1,300 low and intermediate risk SAPIEN 3 valve patients there were excellent clinical outcomes and valve durability irrespective of the patient's annulus size or sex. These data were presented during the late-breaking clini.

Five-Year Data Show Excellent Outcomes for Female and Small Annulus Patients With Edwards TAVR

Becton, Dickinson and Co.

Shares of Becton Dickinson (BDX) advanced close to 3% Monday as the maker of syringes and other medical devices announced it was buying the Critical Care product unit of Edwards Lifesciences (EW) for $4.2 billion in cash.

Becton Dickinson Buys Critical Care Unit From Edwards Lifesciences for $4.2B

Edwards Lifesciences stock rallied Monday on medtech giant Becton Dickinson's plan to buy a key division for $4.2 billion.

Edwards Lifesciences Stock Nears Breakout On A Surprise $4.2 Billion Deal

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

The buyer intends to fund deal with a combination of $1 billion in cash and $3.2 billion of new debt in a transaction that is one of its largest of many.

Becton Dickinson to Acquire Edwards Lifesciences' Unit for $4.2 Billion in Cash

Edwards Lifesciences on Monday said it has agreed to sell its Critical Care products unit to Becton Dickinson in an all-cash transaction valued at $4.2 billion.

News for Edwards Lifesciences Stock (EW)